ReviewJournal of inflammation research2021
The Emerging Clinical Application of m6A RNA Modification in Inflammatory Bowel Disease and Its Associated Colorectal Cancer.
Review in Journal of inflammation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 46 citations in OpenAlex.
- Phenotypic switching of gastrointestinal smooth muscle cells and the regulatory role of macrophages: a literature review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Epitranscriptomic regulation by m6A in immunity and autoimmune disorders: emerging mechanisms and clinical perspectives.Frontiers in immunology · 2026Review
- Review
- The Role of MClinical reviews in allergy & immunology · 2025Review
- Development of a Prognostic m6A-Related lncRNA Signature and Functional Validation of FAM83A-AS1 in Lung Adenocarcinoma.OncoTargets and therapy · 2025Article
- New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy.Frontiers in immunology · 2025Review
- Molecular Insights into RNA Modifications and Their Role in Shaping Immune Responses and Tumor Microenvironments.Current gene therapy · 2025Review
- High WTAP expression level as a promising biomarker for poor prognosis in colorectal cancer: a pilot study.European journal of histochemistry : EJH · 2024Article
- Modulation of host N6-methyladenosine modification by gut microbiota in colorectal cancer.World journal of gastroenterology · 2024Review
- hucMSC-Ex alleviates inflammatory bowel disease in mice by enhancing M2-type macrophage polarization via the METTL3-Slc37a2-YTHDF1 axis.Cell biology and toxicology · 2024Article
- Photosensitive and dual-targeted chromium nanoparticle delivering small interfering RNA YTHDF1 for molecular-targeted immunotherapy in liver cancer.Journal of nanobiotechnology · 2024Article
- YTHDC1 inhibits autophagy-dependent NF-κB signaling by stabilizing Beclin1 mRNA in macrophages.Journal of inflammation (London, England) · 2024Article
- Expression profiles of the lncRNA antisense GAS5-AS1 in colon biopsies from pediatric inflammatory bowel disease patients and its role in regulating sense transcript GAS5.European journal of pediatrics · 2024Article
- Exploring the impact of mFrontiers in immunology · 2024Review
- The role of mGenes & diseases · 2024Review
- Dietary High Glycinin Reduces Growth Performance and Impairs Liver and Intestinal Health Status of Orange-Spotted Grouper (Animals : an open access journal from MDPI · 2023Article
- Human umbilical cord mesenchymal stem cells derived exosome shuttling mir-129-5p attenuates inflammatory bowel disease by inhibiting ferroptosis.Journal of nanobiotechnology · 2023Article
- Exploring m6A-RNA methylation as a potential therapeutic strategy for acute lung injury and acute respiratory distress syndrome.Pulmonary circulation · 2023Review
- The role of mesenchymal stem cell-derived exosome in epigenetic modifications in inflammatory diseases.Frontiers in immunology · 2023Review
- Prognostic Values of METTL3 and Its Roles in Tumor Immune Microenvironment in Pan-Cancer.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methylation, first proposed in DNAs, but later found in RNAs, serves as one of the most widespread epigenetic modifications in eukaryotes, where N6-methyladenosine (m6A) modification has been found to play an important role in a variety of cancers including colorectal cancer (CRC). Under the action of various enzymes and proteins, the regulatory role of m6A in RNAs and immune cells has also been gradually realized. This paper reviews the general biogenesis and effects of m6A, and its emerging crucial role in intestinal mucosal immunity via the regulation of RNAs and immune cells, and thus closely related to the occurrence and development of inflammatory bowel disease (IBD) and CRC. m6A-related genes and regulatory factors are expected to be potential predictive markers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.